Document is current
Any future updates will be listed below
-
Authors
Wartko, Paige D https://orcid.org/0000-0003-0087-3429
Qiu, Hongxiang
Idu, Abisola E.
Yu, Onchee
McCormack, Jennifer
Matthews, Abigail G.
Bobb, Jennifer F.
Saxon, Andrew J.
Campbell, Cynthia I.
Liu, David
Braciszewski, Jordan M.
Murphy, Sean M.
Burganowski, Rachael P.
Murphy, Mark T.
Horigian, Viviana E.
Hamilton, Leah K.
Lee, Amy K.
Boudreau, Denise M.
Bradley, Katharine A.
-
Funding
Funding for this research was provided by:
National Drug Abuse Treatment Clinical Trials Network (UG1DA040314, UG1DA040314, UG1DA040314, UG1DA040314, HHSN271201400028C/75N95019D00013, HHSN271201400028C/75N95019D00013, UG1DA040314, U10DA013714, UG1DA040314, UG1DA040314, UG1DA013035, U10DA013714, U10DA13720, UG1DA040314, UG1DA040314, UG1DA040314, UG1DA040314)
- License Information
-
More Information
Article History
Received: 19 May 2022
Accepted: 30 November 2022
First Online: 29 December 2022
Declarations
:
: A single Institutional Review Board (IRB), Advarra, approved the study including providing waivers of consent and HIPAA authorization, with all sites ceding.
: Not applicable.
: Outside the work of this study, Dr. Wartko was funded through a contract awarded to the Harvard Department of Population Medicine from GlaxoSmithKline to assess medication use in pregnancy. Dr. Wartko receives funding from a research contract awarded to Kaiser Permanente Washington Health Research Institute from Syneos Health to conduct Food and Drug Administration-mandated post-marketing research on the risks of opioid analgesic use. Dr. Boudreau receives funding from a consulting contract from Syneos Health to conduct Food and Drug Administration-mandated post-marketing research on the risks of opioid analgesic use. Dr. Boudreau is now an employee of Genentech, Inc. Ms. Yu was awarded a grant by Bayer AG. Dr. Saxon has received consulting fees from Indivior, Inc., travel support from Alkermes, PLC., and royalties from UptoDate, Inc. Dr. Campbell is supported by grants and contracts from the National Institute on Drug Abuse (UG1-DA040314, R01-DA047405) and the Food and Drug Administration. She has received support managed through her institution from the Industry PMR Consortium, a consortium of companies working together to conduct post-marketing studies required by the Food and Drug Administration that assess risks related to opioid analgesic use.
